The Annual Congress of the European Association of Nuclear Medicine (EANM), a top-tier academic conference in the global nuclear medicine field, will take place at the International Conference Centre in Barcelona, Spain on October 4-8, 2025. Focusing on cutting-edge topics in nuclear medicine, the EANM Congress is renowned for setting international clinical practice standards, and the guidelines it publishes are recognized as the authoritative basis for global nuclear medicine diagnosis and treatment.
The clinical studies of radiopharmaceuticals independently developed by Sinotau have been highly recognized by the congress review committee. Among them, the clinical research findings for the FAP-targeted radioligand therapy XTR017 and the next-generation PSMA-targeted radioligand therapy XTR021 were selected asTop Rated Oral Presentations; the sub-study from the Chinese Phase III registration clinical trial for the SSTR-targeted radioligand therapy XTR008 was selected for the Technologists’ e-Poster Presentations Session and will also be presented orally. This fully demonstrates the company’s innovative strength and technical accumulation in the field of nuclear medicine therapy, laying a solid foundation for subsequent international cooperation.
*FAP: Fibroblast Activation Protein; PSMA: Prostate-Specific Membrane Antigen; SSTR: Somatostatin Receptor
Presentation One
Top Rated Oral Presentation
Presentation Title
A Phase I Clinical Study of Evaluating the Safety and Preliminary Efficacy of177Lu-FAPI-XT in Advanced Solid Tumors with Fibroblast Activation Protein Expression
Session Title
M2M Track – TROP Session – Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Tumor Microenvironment as a Therapeutic Target
Presentation Number: OP-155
Session Date: October 5, 2025
Session Time: 3:00 – 4:30 PM
Session Hall: Room 114
Session Number: 504
Presenter: Liu Honghong (First Medical Center of Chinese PLA General Hospital)
Presentation Two
Top Rated Oral Presentation
Presentation Title
First-in-Human Study of a Novel PSMA-Targeted Radiotherapeutic Agent: Safety, Preliminary Efficacy, and Dosimetry of [177Lu]Lu-PSMA-XT in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Session Title
Theranostics Track – TROP Session – Oncology & Theranostics Committee: Prostate Cancer Therapy: New Tracer
Presentation Number: OP-672
Session Date: October 7, 2025
Session Time: 3:00 – 4:30 PM
Session Hall: Room 117
Session Number: 1506
Presenter: Kang Lei (Peking University First Hospital)
Presentation Three
e-Poster Presentation（With Oral Presentation）
Presentation Title
Pharmacokinetics and Dosimetry of177Lu-DOTATATE in Patients with Advanced well-differentiated, gastroenteropancreatic neuroendocrine tumours: results from a Sub-study of the phase 3 XT-XTR008-3-01 trial
Session Title
Technologists’ e-Poster Presentations Session – Technologists Committee: Techs’ e-Posters
Presentation Number: TEPS-011
Session Date: October 6, 2025
Session Time: 3:40 – 3:44 PM
Session Hall: Room 116
Session Number: 1010
Presenter: Wang Ruimin (First Medical Center of Chinese PLA General Hospital)
About Sinotau
Sinotau, founded in 2005, is a front-runner and leader in the Chinese radiopharmaceutical market, possessing end-to-end capabilities across the entire industry value chain, from radionuclide development and production to radiopharmaceutical R&D, manufacturing, and commercialization. Adhering to its mission of “Invent radiopharmaceuticals for lives”, Sinotau is rooted in China with a global vision. The company is headquartered in Beijing, with an R&D center in Shanghai, and modern radiopharmaceutical production bases in Jiangsu, Guangdong, and Sichuan; it also has a branch in the United States. Driven by unmet clinical needs, Sinotau focuses on three major therapeutic areas: neurodegenerative diseases, cardiovascular diseases, and oncology, having established a comprehensive, differentiated, and synergistic product portfolio with significant potential in radiopharmaceutical theranostics. Among its products, Florbetaben [18F] Injection is the first innovative PET tracer approved for marketing in China in nearly 20 years; its diverse pipeline, at various stages, broadly covers global innovative targets in radiopharmaceuticals, demonstrating the strong competitiveness of our pipeline and leading the new speed of innovative radiopharmaceutical development.
Forward-Looking Statements
This press release may contain certain forward-looking statements. These statements are inherently subject to significant risks and uncertainties. When terms like “anticipate”, “believe”, “estimate”, “expect”, “intend”, and similar expressions are used in connection with the Company, they are intended to identify forward-looking statements. The Company undertakes no obligation to update these predictive statements continuously.
These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts, and understanding of the Company’s management regarding future events at the time the statements are made. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some beyond the Company’s control, that are difficult to predict. Consequently, actual results may differ materially from the information contained in the forward-looking statements due to future changes and developments in our business, competitive environment, and political, economic, legal, and social conditions in China.
The Company, its directors, employees, and agents assume no obligation to (a) correct or update any forward-looking statements contained in this press release; or (b) compensate for any losses should any forward-looking statement fail to materialize or prove to be incorrect.